495 related articles for article (PubMed ID: 15812574)
1. Novel approaches in the therapy of metastatic renal cell carcinoma.
Lam JS; Leppert JT; Belldegrun AS; Figlin RA
World J Urol; 2005 Jul; 23(3):202-12. PubMed ID: 15812574
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
3. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
Lam JS; Belldegrun AS; Figlin RA
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6304S-9S. PubMed ID: 15448022
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma: current status and emerging therapies.
Nelson EC; Evans CP; Lara PN
Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
[TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection.
Breda A; Konijeti R; Lam JS
Expert Rev Anticancer Ther; 2007 Jun; 7(6):847-62. PubMed ID: 17555395
[TBL] [Abstract][Full Text] [Related]
6. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
7. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.
Lam JS; Leppert JT; Figlin RA; Belldegrun AS
Urology; 2005 Nov; 66(5 Suppl):1-9. PubMed ID: 16194700
[TBL] [Abstract][Full Text] [Related]
8. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
9. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
10. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
Thomas JS; Kabbinavar F
Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma: basic biology and current approaches to therapy.
Belldegrun A; Abi-Aad AS; Figlin RA; deKernion JB
Semin Oncol; 1991 Oct; 18(5 Suppl 7):96-101. PubMed ID: 1948136
[TBL] [Abstract][Full Text] [Related]
12. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
[TBL] [Abstract][Full Text] [Related]
13. [The present state and the future perspective of immunotherapy of renal cell carcinoma].
Kawashima H
Nihon Rinsho; 2015 Jan; 73(1):167-74. PubMed ID: 25626324
[TBL] [Abstract][Full Text] [Related]
14. Current management of advanced and metastatic renal cell carcinoma.
Ather MH; Masood N; Siddiqui T
Urol J; 2010; 7(1):1-9. PubMed ID: 20209445
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for kidney cancer in urologic practice.
Haas NB; Uzzo RG
Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
18. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
19. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in renal cell carcinoma.
Shuch BM; Lam JS; Belldegrun AS; Figlin RA
Semin Oncol; 2006 Oct; 33(5):563-75. PubMed ID: 17045085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
